A dual-ligand approach for enhancing targeting selectivity of therapeutic nanocarriers

Journal of Controlled Release

Volumn 114, Issue 3, 2006, Pages 277-287

  Saul, Justin M ^a,b   Annapragada, Ananth V ^c   Bellamkonda, Ravi V ^a  

^a GEORGIA INSTITUTE OF TECHNOLOGY   (United States)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

^c UNIVERSITY OF TEXAS   (United States)

Author keywords

Cancer; Drug delivery; Ligand; Liposome; Targeting

Indexed keywords

ANTIBODIES; CELLS; DRUG THERAPY; EPIDEMIOLOGY; LIPIDS; TUMORS;

DRUG DELIVERY; LIGANDS; LIPOSOMES; TARGETING SELECTIVITY;

NANOSTRUCTURED MATERIALS;

CELL SURFACE RECEPTOR; DOXORUBICIN; DRUG CARRIER; EPIDERMAL GROWTH FACTOR RECEPTOR; FOLATE RECEPTOR; FOLIC ACID; LIGAND; LIPOSOME; MONOCLONAL ANTIBODY; NANOPARTICLE;

ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DRUG CONJUGATION; DRUG DESIGN; DRUG SELECTIVITY; DRUG TARGETING; HUMAN; HUMAN CELL; IN VITRO STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR BLOCKING; TARGET CELL; TUMOR CELL;

ANTINEOPLASTIC AGENTS; CELL SURVIVAL; CHEMISTRY, PHARMACEUTICAL; DOXORUBICIN; DRUG CARRIERS; FOLIC ACID; HUMANS; KB CELLS; LIGANDS; LIPOSOMES; NANOSTRUCTURES;

EID: 33748165210     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jconrel.2006.05.028     Document Type: Article

References (49)

1. Torp S.H., Helseth E., Dalen A., and Unsgaard G. Epidermal growth factor receptor expression in human gliomas. Cancer Immunol. Immunother. 33 1 (1991) 61-64
2. Santini J., Formento J.L., Francoual M., Milano G., Schneider M., Dassonville O., and Demard F. Characterization, quantification, and potential clinical value of the epidermal growth factor receptor in head and neck squamous cell carcinomas. Head Neck 13 2 (1991) 132-139
3. Rusch V., Mendelsohn J., and Dmitrovsky E. The epidermal growth factor receptor and its ligands as therapeutic targets in human tumors. Cytokine Growth Factor Rev. 7 2 (1996) 133-141
4. Weitman S.D., Lark R.H., Coney L.R., Fort D.W., Frasca V., Zurawski Jr. V.R., and Kamen B.A. Distribution of the folate receptor GP38 in normal and malignant cell lines and tissues. Cancer Res. 52 12 (1992) 3396-3401
5. Recht L., Torres C.O., Smith T.W., Raso V., and Griffin T.W. Transferrin receptor in normal and neoplastic brain tissue: implications for brain-tumor immunotherapy. J. Neurosurg. 72 6 (1990) 941-945
6. Simpson B.J., Phillips H.A., Lessells A.M., Langdon S.P., and Miller W.R. c-erbB growth-factor-receptor proteins in ovarian tumours. Int. J. Cancer 64 3 (1995) 202-206
7. Blume G., Cevc G., Crommelin M.D., Bakker-Woudenberg I.A., Kluft C., and Storm G. Specific targeting with poly(ethylene glycol)-modified liposomes: coupling of homing devices to the ends of the polymeric chains combines effective target binding with long circulation times. Biochim. Biophys. Acta 1149 1 (1993) 180-184
8. Kung V.T., and Redemann C.T. Synthesis of carboxyacyl derivatives of phosphatidylethanolamine and use as an efficient method for conjugation of protein to liposomes. Biochim. Biophys. Acta 862 2 (1986) 435-439
9. Lukyanov A.N., Elbayoumi T.A., Chakilam A.R., and Torchilin V.P. Tumor-targeted liposomes: doxorubicin-loaded long-circulating liposomes modified with anti-cancer antibody. J. Control. Release 100 1 (2004) 135-144
10. Yoo H.S., and Park T.G. Folate receptor targeted biodegradable polymeric doxorubicin micelles. J. Control. Release 96 2 (2004) 273-283
11. Xie Y., Ye L., Zhang X., Cui W., Lou J., Nagai T., and Hou X. Transport of nerve growth factor encapsulated into liposomes across the blood-brain barrier: In vitro and in vivo studies. J. Control. Release 105 1-2 (2005) 106-119
12. Eavarone D.A., Yu X., and Bellamkonda R.V. Targeted drug delivery to C6 glioma by transferrin-coupled liposomes. J. Biomed. Mater. Res. 51 1 (2000) 10-14
13. Leamon C.P., Cooper S.R., and Hardee G.E. Folate-liposome-mediated antisense oligodeoxynucleotide targeting to cancer cells: evaluation in vitro and in vivo. Bioconjug. Chem. 14 4 (2003) 738-747
14. Bohl Kullberg M., Mann K., and Owens J.L. Improved drug delivery to cancer cells: a method using magnetoliposomes that target epidermal growth factor receptors. Med. Hypotheses 64 3 (2005) 468-470
15. Allen T.M., Brandeis E., Hansen C.B., Kao G.Y., and Zalipsky S. A new strategy for attachment of antibodies to sterically stabilized liposomes resulting in efficient targeting to cancer cells. Biochim. Biophys. Acta 1237 2 (1995) 99-108
16. Saul J.M., Annapragada A., Natarajan J.V., and Bellamkonda R.V. Controlled targeting of liposomal doxorubicin via the folate receptor in vitro. J. Control. Release 92 1-2 (2003) 49-67
17. Ghaghada K.B., Saul J., Natarajan J.V., Bellamkonda R.V., and Annapragada A.V. Folate targeting of drug carriers: a mathematical model. J. Control. Release 104 1 (2005) 113-128
18. Zalipsky S., Brandeis E., Newman M.S., and Woodle M.C. Long circulating, cationic liposomes containing amino-PEG-phosphatidylethanolamine. FEBS Lett. 353 1 (1994) 71-74
19. Gabizon A., Horowitz A.T., Goren D., Tzemach D., Mandelbaum-Shavit F., Qazen M.M., and Zalipsky S. Targeting folate receptor with folate linked to extremities of poly(ethylene glycol)-grafted liposomes: in vitro studies. Bioconjug. Chem. 10 2 (1999) 289-298
20. Lopes de Menezes D.E., Kirchmeier M.J., Gange J.-F., Pilarski L.M., and Allen T.M. Cellular trafficking and cytotoxicity of anti-cd19-targeted liposomal doxorubicin in B lymphoma cells. J. Liposome Res. 9 2 (1999) 199-228
21. Bolotin E.M., Cohen R., Bar L.K., Emanuel N., Ninio S., Lasic D.D., and Barenholz Y. Ammonium sulfate gradients for efficient and stable remote loading of amphipathic weak bases into liposomes and ligandoliposomes. J. Liposome Res. 4 1 (1994) 455-479
22. Lee R.J., and Low P.S. Delivery of liposomes into cultured KB cells via folate receptor-mediated endocytosis. J. Biol. Chem. 269 5 (1994) 3198-3204
23. Qi L., Singh R.P., Lu Y., Agarwal R., Harrison G.S., Franzusoff A., and Glode L.M. Epidermal growth factor receptor mediates silibinin-induced cytotoxicity in a rat glioma cell line. Cancer Biol. Ther. 2 5 (2003) 526-531
24. Goren D., Horowitz A.T., Tzemach D., Tarshish M., Zalipsky S., and Gabizon A. Nuclear delivery of doxorubicin via folate-targeted liposomes with bypass of multidrug-resistance efflux pump. Clin. Cancer Res. 6 5 (2000) 1949-1957
25. Sudimack J., and Lee R.J. Targeted drug delivery via the folate receptor. Adv. Drug Deliv. Rev. 41 2 (2000) 147-162
26. Li H., and Qian Z.M. Transferrin/transferrin receptor-mediated drug delivery. Med. Res. Rev. 22 3 (2002) 225-250
27. Baselga J. The EGFR as a target for anticancer therapy-focus on cetuximab. Eur. J. Cancer 37 Suppl 4 (2001) S16-S22
28. Ishida O., Maruyama K., Tanahashi H., Iwatsuru M., Sasaki K., Eriguchi M., and Yanagie H. Liposomes bearing polyethyleneglycol-coupled transferrin with intracellular targeting property to the solid tumors in vivo. Pharm. Res. 18 7 (2001) 1042-1048
29. Huwyler J., Yang J., and Pardridge W.M. Receptor mediated delivery of daunomycin using immunoliposomes: pharmacokinetics and tissue distribution in the rat. J. Pharmacol. Exp. Ther. 282 3 (1997) 1541-1546
30. Kong G., Braun R.D., and Dewhirst M.W. Characterization of the effect of hyperthermia on nanoparticle extravasation from tumor vasculature. Cancer Res. 61 7 (2001) 3027-3032
31. Zhang Y., Zhu C., and Pardridge W.M. Antisense gene therapy of brain cancer with an artificial virus gene delivery system. Mol. Ther. 6 1 (2002) 67-72
32. Zhang Y., Zhang Y.F., Bryant J., Charles A., Boado R.J., and Pardridge W.M. Intravenous RNA interference gene therapy targeting the human epidermal growth factor receptor prolongs survival in intracranial brain cancer. Clin. Cancer Res. 10 11 (2004) 3667-3677
33. Sapra P., and Allen T.M. Improved outcome when B-cell lymphoma is treated with combinations of immunoliposomal anticancer drugs targeted to both the CD19 and CD20 epitopes. Clin. Cancer Res. 10 7 (2004) 2530-2537
34. Grill J., Van Beusechem V.W., Van Der Valk P., Dirven C.M., Leonhart A., Pherai D.S., Haisma H.J., Pinedo H.M., Curiel D.T., and Gerritsen W.R. Combined targeting of adenoviruses to integrins and epidermal growth factor receptors increases gene transfer into primary glioma cells and spheroids. Clin. Cancer Res. 7 3 (2001) 641-650
35. Eniola A.O., Willcox P.J., and Hammer D.A. Interplay between rolling and firm adhesion elucidated with a cell-free system engineered with two distinct receptor-ligand pairs. Biophys. J. 85 4 (2003) 2720-2731
36. Roth A., Rohrbach F., Weth R., Frisch B., Schuber F., and Wels W.S. Induction of effective and antigen-specific antitumour immunity by a liposomal ErbB2/HER2 peptide-based vaccination construct. Br. J. Cancer 92 8 (2005) 1421-1429
37. Allen T.M., Hansen C., Martin F., Redemann C., and Yau-Young A. Liposomes containing synthetic lipid derivatives of poly(ethylene glycol) show prolonged circulation half-lives in vivo. Biochim. Biophys. Acta 1066 1 (1991) 29-36
38. Klibanov A.L., Maruyama K., Torchilin V.P., and Huang L. Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes. FEBS Lett. 268 1 (1990) 235-237
39. Wang S., Lee R.J., Cauchon G., Gorenstein D.G., and Low P.S. Delivery of antisense oligodeoxyribonucleotides against the human epidermal growth factor receptor into cultured KB cells with liposomes conjugated to folate via polyethylene glycol. Proc. Natl. Acad. Sci. U. S. A. 92 8 (1995) 3318-3322
40. Kullberg E.B., Nestor M., and Gedda L. Tumor-cell targeted epidermal growth factor liposomes loaded with boronated acridine: uptake and processing. Pharm. Res. 20 2 (2003) 229-236
41. Iinuma H., Maruyama K., Okinaga K., Sasaki K., Sekine T., Ishida O., Ogiwara N., Johkura K., and Yonemura Y. Intracellular targeting therapy of cisplatin-encapsulated transferrin-polyethylene glycol liposome on peritoneal dissemination of gastric cancer. Int. J. Cancer 99 1 (2002) 130-137
42. Chiu S.J., Ueno N.T., and Lee R.J. Tumor-targeted gene delivery via anti-HER2 antibody (trastuzumab, Herceptin) conjugated polyethylenimine. J. Control. Release 97 2 (2004) 357-369
43. Shuai X., Ai H., Nasongkla N., Kim S., and Gao J. Micellar carriers based on block copolymers of poly(epsilon-caprolactone) and poly(ethylene glycol) for doxorubicin delivery. J. Control. Release 98 3 (2004) 415-426
44. Liang H.F., Yang T.F., Huang C.T., Chen M.C., and Sung H.W. Preparation of nanoparticles composed of poly(gamma-glutamic acid)-poly(lactide) block copolymers and evaluation of their uptake by HepG2 cells. J. Control. Release 105 3 (2005) 213-225
45. Mamot C., Drummond D.C., Greiser U., Hong K., Kirpotin D.B., Marks J.D., and Park J.W. Epidermal growth factor receptor (EGFR)-targeted immunoliposomes mediate specific and efficient drug delivery to EGFR- and EGFRvIII-overexpressing tumor cells. Cancer Res. 63 12 (2003) 3154-3161
46. Turk M.J., Waters D.J., and Low P.S. Folate-conjugated liposomes preferentially target macrophages associated with ovarian carcinoma. Cancer Lett. 213 2 (2004) 165-172
47. Salomon D.S., Brandt R., Ciardiello F., and Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit. Rev. Oncol.Hematol. 19 3 (1995) 183-232
48. Sato J.D., Kawamoto T., Le A.D., Mendelsohn J., Polikoff J., and Sato G.H. Biological effects in vitro of monoclonal antibodies to human epidermal growth factor receptors. Mol. Biol. Med. 1 5 (1983) 511-529
49. Drebin J.A., Link V.C., and Greene M.I. Monoclonal antibodies specific for the neu oncogene product directly mediate anti-tumor effects in vivo. Oncogene 2 4 (1988) 387-394